pindolol has been researched along with Hepatocellular Carcinoma in 1 studies
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wicks, WD | 1 |
| Leichtling, BH | 1 |
| Wimalasena, J | 1 |
| Roper, MD | 1 |
| Su, JL | 1 |
| Su, YF | 1 |
| Howell, S | 1 |
| Harden, TK | 1 |
| Wolfe, BB | 1 |
1 other study available for pindolol and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Regulation of cAMP metabolism, protein kinase activation, and specific enzyme synthesis in cultured hepatoma cells.
Topics: Adenylyl Cyclases; Carcinoma, Hepatocellular; Cells, Cultured; Cholera Toxin; Cyclic AMP; Enzyme Act | 1978 |